for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Allogene Therapeutics Inc

ALLO.OQ

現在値

15.82USD

変化

-0.12(-0.75%)

出来高

281,029

本日のレンジ

15.44

 - 

15.93

52週レンジ

12.90

 - 

39.08

∙ 約20分前の相場を表示しています。

適時開示

Allogene Reports FDA Clinical Hold Of AlloCAR T Trials Based On Single Patient Case In Alpha2 Trial

Oct 7 (Reuters) - Allogene Therapeutics Inc <ALLO.O>::ALLOGENE THERAPEUTICS REPORTS FDA CLINICAL HOLD OF ALLOCAR T TRIALS BASED ON A SINGLE PATIENT CASE IN ALPHA2 TRIAL.ALLOGENE THERAPEUTICS - BELIEVES DATA FROM ALPHA TRIALS DEMONSTRATES A FAVORABLE CLINICAL PROFILE OF ALLO-501A.ALLOGENE THERAPEUTICS - FDA CONTINUES TO REVIEW END OF PHASE 1 MATERIALS FOR A PHASE 2 PIVOTAL TRIAL OF ALLO-501A.ALLOGENE - TESTING IN A PATIENT WITH LOW BLOOD COUNTS SHOWED CHROMOSOMAL ABNORMALITY IN ALLO-501A CAR T CELLS OF UNCLEAR CLINICAL SIGNIFICANCE.ALLOGENE THERAPEUTICS INC - INVESTIGATION IS UNDERWAY TO FURTHER CHARACTERIZE OBSERVED ABNORMALITY.

Allogene Therapeutics Receives FDA ODD For ALLO-715

Aug 12 (Reuters) - Allogene Therapeutics Inc <ALLO.O>::ALLOGENE THERAPEUTICS RECEIVES FDA ORPHAN DRUG DESIGNATION (ODD) FOR ALLO-715 FOR THE TREATMENT OF MULTIPLE MYELOMA (MM).ALLOGENE THERAPEUTICS INC - NEXT CLINICAL UPDATE FROM ALLO-715 UNIVERSAL TRIAL PLANNED FOR LATE 2021.ALLOGENE THERAPEUTICS INC - ODD FOLLOWS RMAT DESIGNATION GRANTED TO ALLO-715 BY FDA IN MULTIPLE MYELOMA PATIENTS.

Allogene Therapeutics Inc- QTRLY Loss Per Share $0.53

Allogene Therapeutics Inc <ALLO.O>::ALLOGENE THERAPEUTICS REPORTS SECOND QUARTER 2021 FINANCIAL RESULTS.QTRLY LOSS PER SHARE $0.53.CONTINUES TO EXPECT FULL YEAR GAAP OPERATING EXPENSES TO BE BETWEEN $300 MILLION AND $330 MILLION.

Allogene Therapeutics Granted FDA Fast Track Designation For Allo-605 For The Treatment Of Relapsed/Refractory Multiple Myeloma

June 30 (Reuters) - Allogene Therapeutics Inc <ALLO.O>::ALLOGENE THERAPEUTICS GRANTED FDA FAST TRACK DESIGNATION FOR ALLO-605, THE FIRST TURBOCAR T CELL THERAPY, FOR THE TREATMENT OF RELAPSED/REFRACTORY MULTIPLE MYELOMA.

Allogene Reports Results From Studies Of ALLO-501 And ALLO-501A In Relapsed/Refractory Non-Hodgkin Lymphoma

May 19 (Reuters) - Allogene Therapeutics Inc <ALLO.O>::ALLOGENE THERAPEUTICS CD19 FORUM HIGHLIGHTS POSITIVE RESULTS FROM PHASE 1 STUDIES OF ALLO-501 AND ALLO-501A IN RELAPSED/REFRACTORY NON-HODGKIN LYMPHOMA AND PLAN TO INITIATE PIVOTAL STUDY IN 2021.ALLOGENE THERAPEUTICS INC - OVERALL RESPONSE RATE (ORR) OF 75% AND CR RATE OF 50% ACROSS HISTOLOGIES IN CAR T NAÏVE PATIENTS.ALLOGENE THERAPEUTICS INC - 98% OF ENROLLED PATIENTS RECEIVED ALLO-501 WITH A MEDIAN TIME OF 5 DAYS FROM ENROLLMENT TO START OF THERAPY.ALLOGENE THERAPEUTICS - INITIATION OF PIVOTAL TRIAL OF ALLO-501A PLANNED FOR LATE 2021.ALLOGENE THERAPEUTICS INC - INTERIM PHASE 1 ALPHA2 DATA DEMONSTRATED A COMPARABLE EFFICACY AND SAFETY PROFILE FOR ALLO-501A RELATIVE TO ALLO-501.ALLOGENE THERAPEUTICS INC - DURING PHASE 1 ALLO-501 ALPHA TRIAL STUDY, THERE WERE FIVE TREATMENT-EMERGENT DEATHS IN ABSENCE OF DISEASE PROGRESSION.

Allogene Therapeutics Inc - QTRLY Net Loss Per Share, Basic And Diluted $0.25

May 5 (Reuters) - Allogene Therapeutics Inc <ALLO.O>::ALLOGENE THERAPEUTICS REPORTS FIRST QUARTER 2021 FINANCIAL RESULTS.QTRLY NET LOSS PER SHARE, BASIC AND DILUTED $0.25.CONTINUES TO EXPECT FULL YEAR GAAP OPERATING EXPENSES TO BE BETWEEN $300 MILLION AND $330 MILLION.Q1 EARNINGS PER SHARE VIEW $-0.46 -- REFINITIV IBES DATA.

Allogene Therapeutics Q4 Loss Per Share $0.53

Feb 25 (Reuters) - Allogene Therapeutics Inc <ALLO.O>::ALLOGENE THERAPEUTICS REPORTS FOURTH QUARTER AND FULL YEAR 2020 FINANCIAL RESULTS AND CORPORATE UPDATE.Q4 LOSS PER SHARE $0.53.Q4 EARNINGS PER SHARE ESTIMATE $-0.56 -- REFINITIV IBES DATA.CO HAD $1.0 BILLION IN CASH, CASH EQUIVALENTS, AND INVESTMENTS AS OF DECEMBER 31, 2020.EXPECTS FULL YEAR 2021 GAAP OPERATING EXPENSES TO BE BETWEEN $300 MILLION AND $330 MILLION.ON TRACK TO SUBMIT IND IN 1H 2021 FOR ALLO-605 IN MULTIPLE MYELOMA, FIRST TURBOCAR TARGETING BCMA.CGMP MANUFACTURING FACILITY TO BEGIN PRODUCTION IN 2021.

Allogene Therapeutics Receives Ind Clearance From The U.S. Food And Drug Administration For Allo-715 In Combination With Nirogacestat In Relapsed/Refractory Multiple Myeloma

Dec 23 (Reuters) - Allogene Therapeutics Inc <ALLO.O>::ALLOGENE THERAPEUTICS RECEIVES IND CLEARANCE FROM THE U.S. FOOD AND DRUG ADMINISTRATION FOR ALLO-715 IN COMBINATION WITH NIROGACESTAT IN RELAPSED/REFRACTORY MULTIPLE MYELOMA.ALLOGENE THERAPEUTICS INC - ENROLLMENT IN COHORT IS EXPECTED TO BEGIN IN Q1 OF 2021 FOR PHASE 1 CLINICAL TRIAL.ALLOGENE THERAPEUTICS - CO IS SPONSORING AND CONDUCTING PHASE 1 STUDY TO EVALUATE SAFETY, TOLERABILITY AND PRELIMINARY EFFICACY OF COMBINATION.ALLOGENE- ASSUMING ALL DEVELOPMENT COSTS ASSOCIATED WITH STUDY,EXEPT EXPENSES FOR MANUFACTURING OF NIROGACESTAT,CERTAIN EXPENSES RELATED TO IP RIGHTS.

Allogene, Overland Form JV In Greater China To Develop, Commercialize AlloCAR T Cell Therapies

Dec 15 (Reuters) - Allogene Therapeutics Inc <ALLO.O>::ALLOGENE THERAPEUTICS AND OVERLAND PHARMACEUTICALS FORM JOINT VENTURE IN GREATER CHINA TO DEVELOP AND COMMERCIALIZE ALLOCAR T™ CELL THERAPIES.ALLOGENE THERAPEUTICS INC - OVERLAND TO INVEST $117 MILLION IN CAPITAL, WHICH INCLUDES AN UPFRONT PAYMENT TO ALLOGENE.ALLOGENE THERAPEUTICS INC - ALLOGENE OVERLAND WILL RECEIVE EXCLUSIVE LICENSE TO ALLOCAR T CANDIDATES DIRECTED AT FOUR TARGETS.ALLOGENE THERAPEUTICS INC - OVERLAND AND ALLOGENE ARE SOLE EQUITY HOLDERS IN ALLOGENE OVERLAND.ALLOGENE THERAPEUTICS INC - ALLOGENE WILL BE ELIGIBLE TO RECEIVE A MILESTONE PAYMENT PER PRODUCT FOR EACH FIRST REGULATORY APPROVAL IN CHINA.

Allogene Therapeutics Announces Preclinical Findings Supporting Allo-605, First Anti-Bcma Turbocar T Cell Therapy

Dec 7 (Reuters) - Allogene Therapeutics Inc <ALLO.O>::ALLOGENE THERAPEUTICS INC - ANNOUNCED PRECLINICAL FINDINGS SUPPORTING ALLO-605, FIRST ANTI-BCMA TURBOCAR T CELL THERAPY.ALLOGENE THERAPEUTICS INC - ALLO-605 DEMONSTRATED ENHANCED KILLING OF MULTIPLE MYELOMA CELLS AND PERSISTENCE RELATIVE TO BCMA CAR T.ALLOGENE THERAPEUTICS INC - INVESTIGATIONAL NEW DRUG APPLICATION FOR ALLO-605 EXPECTED IN FIRST HALF OF 2021.

金融情報はリフィニティブから。すべての情報は少なくとも20分遅れで表示されています。

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up